GE Healthcare, Geron Expand Deal for Stem Cell-based Assays

Oct 08, 2012

|

NEW YORK (GenomeWeb News) – GE Healthcare said today it has expanded its licensing agreement with Geron for the development of cellular assays and models derived from embryonic stem cells.

The assays and models are for use in drug discovery and toxicity screening, and under the terms of the expanded deal, GE has exclusive rights to Geron's IP and know-how for developing and selling cellular assays derived from induced pluripotent stem cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

This Week in PLOS

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

Isolation Worries

An opinion piece at Bloomberg discusses China's stance on genomic research.

Shaken Identity

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Free-Ish

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

Main menu